Oppenheimer analyst Trevor Allred upgraded BridgeBio (BBIO) to Outperform from Perform with a $60 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma Enters Royalty Purchase Agreement
- Strategic Financial Maneuvers and Growth Potential: BridgeBio Pharma’s Path to Profitability
- BridgeBio raises $300M via parital capped monetization of European royalty
- 3 Best Stocks to Buy Now, 6/30/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 6/26/2025, According to Top Analysts